# What a New Infant Cohort Really Shows About Cannabis and Breastfeeding > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/breastfeeding-after-prenatal-cannabis-exposure/ > **Published:** 2026-04-23T23:38:10-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:01:09-04:00 > **Clinical Summary:** Breastfeeding after prenatal cannabis exposure: what a new infant cohort shows, what it does not prove, and how clinicians should counsel families. --- CED Clinical Relevance #78 Strong Clinical Relevance Useful for nuanced counseling, but not evidence that cannabis exposure during lactation is safe. Clinical Insight | CED Clinic This study supports careful, individualized counseling after prenatal cannabis exposure has already occurred. It does not show that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during breastfeeding is safe. Pregnancy Breastfeeding Pediatrics Development Counseling Audience Patients, parents, pediatric clinicians, obstetric clinicians, lactation specialists Primary Topic Breastfeeding counseling after prenatal cannabis exposure Source [Read the full article](https://doi.org/10.1177/15568253251409805) ## Breastfeeding After Prenatal Cannabis Exposure: What This Cohort Can, and Cannot, Tell Us A 1,520-infant retrospective cohort found no statistically significant adjusted difference in coded developmental delay between breastfed and non-breastfed infants whose mothers tested positive for cannabis at delivery. The result is clinically useful, but it should not be misread as proof that cannabis use during lactation is safe. What This Study Teaches Us This paper suggests that, among infants with prenatal cannabis exposure documented at delivery, breastfeeding status was not associated with a statistically significant difference in later coded developmental delay after adjustment. That finding supports more careful counseling, but it does not prove cannabis exposure through breast milk is harmless. Why This Matters Breastfeeding advice sits at the intersection of infant nutrition, [maternal health](https://cedclinic.com/recreational-cannabis-birth-outcomes-study-colorado/), stigma, and imperfect evidence. Major professional guidance still advises avoiding cannabis use during pregnancy and lactation, yet feeding decisions often occur in real life after exposure has already happened. This study matters because it argues against turning uncertainty into blunt advice that may reduce breastfeeding without clearly improving developmental outcomes. Study Snapshot Study Type Retrospective cohort study Population 1,520 infants born from 2013 to 2019 whose mothers tested positive for cannabis at delivery Exposure or Intervention Breastfeeding status among infants with prenatal cannabis exposure Comparator Breastfed versus not breastfed Primary Outcomes Developmental delay identified through ICD-9/10 codes for delayed milestones or speech disorders Sample Size or Scope 818 not breastfed, 702 breastfed Journal Breastfeeding Medicine Year First published online December 23, 2025 DOI 10.1177/15568253251409805 Funding or Conflicts Verify from full article before final publication if not visible in the abstract view. Clinical Bottom Line This paper supports nuance, not reassurance. It suggests breastfeeding should not automatically be treated as the clearly more harmful option among infants already exposed prenatally, but it does not overturn the broader recommendation to avoid cannabis use during pregnancy and lactation whenever possible. What This Paper Looked At The investigators used a hospital-based perinatal repository and included infants whose mothers had a positive cannabis urine test at delivery. Breastfeeding status came from birth certificate data. Developmental delay was identified later through billing codes for delayed milestones or speech disorders. The statistical model adjusted for maternal tobacco use, prematurity, and birth year. That design makes the paper practical and clinically recognizable, but it also means this is not a direct measure of cannabinoid exposure through milk, nor a prospective developmental assessment with standardized testing. What the Paper Found In the unadjusted analysis, infants who were not breastfed had higher odds of developmental delay coding. Once the model adjusted for key covariates, that association was no longer statistically significant. The authors concluded that developmental outcomes did not differ by breastfeeding status among infants with prenatal cannabis exposure. The most responsible reading is narrow: this is a signal against overly blunt feeding advice in already-exposed dyads, not evidence that cannabis exposure during lactation is safe or clinically advisable. How Strong Is This Evidence? Moderate for generating counseling nuance, weak for proving safety. The cohort is larger than many perinatal cannabis datasets and uses a concrete exposure screen at delivery, which is helpful. But it remains retrospective, non-randomized, and outcome ascertainment relied on diagnostic coding rather than formal neurodevelopmental testing. Where This Paper Deserves Skepticism Exposure precision is limited. A positive maternal test at delivery does not quantify dose, frequency, route, potency, or continued postpartum use. The developmental outcome is blunt. ICD codes can miss subtler neurodevelopmental effects and are not interchangeable with standardized developmental assessment. Residual confounding remains possible. Important social and clinical differences between breastfeeding and non-breastfeeding families can persist even after adjustment. What This Paper Does Not Show It does not prove cannabis exposure through breast milk is safe. It does not show that cannabis should be used during lactation. It does not answer questions about long-term executive function, attention, school-age behavior, or dose-response risk. How This Fits With the Broader Clinical Conversation Perinatal cannabis counseling is unusually vulnerable to false certainty. Some public narratives overstate harm from any single exposure detail. Others overread observational null findings as reassurance. Neither move is clinically responsible. The more defensible position is this: avoid cannabis use during pregnancy and lactation when possible, but when clinicians are counseling an already-exposed dyad about infant feeding, breastfeeding decisions should be individualized rather than driven by theoretical alarm alone. Dr. Caplan’s Take *This is the kind of paper that helps prevent a counseling mistake. It does not make cannabis in lactation look proven safe. What it does do is push us away from simplistic advice that ignores the well-established benefits of breastfeeding and the reality that many clinical decisions happen after prenatal exposure has already occurred.* *In that setting, the responsible conversation is individualized, nonjudgmental, and evidence-literate. The clinical task is not to minimize cannabis exposure. It is to avoid replacing one uncertainty with another oversimplification.* What a Careful Reader Should Take Away This is a useful cohort, not a definitive answer. Its main practical message is that breastfeeding status was not associated with a statistically significant adjusted difference in coded developmental delay among infants already exposed prenatally. That should make clinical counseling more nuanced while leaving the broader precautionary stance intact. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Expecting and Experimenting with Cannabis A broader evidence review on pregnancy, cannabis exposure, and how to read the literature without flattening a difficult clinical topic into slogans. [Read article](https://cedclinic.com/expecting-and-experimenting-with-cannabis/) Prenatal Cannabis Exposure Study: What This Paper Found, What It Did Not, and Why Policy Context Matters A careful review of meconium-based prenatal exposure data that helps frame how outcomes research in this space can be distorted by design and surveillance effects. [Explore evidence](https://cedclinic.com/prenatal-cannabis-exposure-study-meconium-medicaid-developmental-delay/) Clearing the Haze: Cannabis Use in Pregnancy and Long-Term Outcomes A practical counseling-oriented companion for discussing pregnancy, [fetal development](https://cedclinic.com/prenatal-cannabinoid-exposure-reproductive-health-insights/), and why longitudinal interpretation still requires restraint. [Continue reading](https://cedclinic.com/cannabis-use-pregnancy-risks-clearing-the-haze/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [Share on X](https://x.com/intent/tweet?text=Breastfeeding%20After%20Prenatal%20Cannabis%20Exposure) [Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https://cedclinic.com/) [Share on BlueSky](https://bsky.app/) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [Read more on Substack](https://substack.com/@doctorapproved) [Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) **Source:** Nidey N, McAllister JM, Terplan M, Kair LR. *Breastfeeding and Developmental Outcomes in Infants with Prenatal Cannabis Exposure: A Retrospective Cohort Study.* *Breastfeeding Medicine.* First published online December 23, 2025. DOI: 10.1177/15568253251409805. [Read the source article →](https://doi.org/10.1177/15568253251409805) ## FAQ Does this study mean cannabis is safe during breastfeeding? No. The study did not prove safety. It found no statistically significant adjusted difference in coded developmental delay by breastfeeding status within a cohort already exposed prenatally. Why is the paper useful if it does not prove safety? Because it helps refine counseling after prenatal exposure has already occurred. It argues against overstating what is known about breastfeeding-related harm in this specific context. What should clinicians say right now? Current professional guidance still supports avoiding [cannabis in pregnancy](https://cedclinic.com/cannabis-in-pregnancy-study-5-crucial-insights/) and lactation. When feeding decisions must be made after prenatal exposure, counseling should be individualized, with attention to breastfeeding benefits, ongoing exposure risk, and the limits of the evidence. What is the safest interpretation for patients? Avoid cannabis exposure during pregnancy and lactation when possible. If exposure has already occurred, decisions about breastfeeding should be made with a clinician who can weigh infant nutrition, maternal health, exposure pattern, and family context. Which infants were included in this breastfeeding and cannabis study? The retrospective cohort included 1,520 infants born from 2013 to 2019 whose mothers had a positive cannabis urine test at delivery, drawn from a hospital-based perinatal repository. Of these, 702 were breastfed and 818 were not, with breastfeeding status taken from birth certificate data. Were non-breastfed infants more likely to have developmental delay? Only before adjustment. In the unadjusted analysis, infants who were not breastfed had higher odds of developmental delay coding. After the model adjusted for maternal tobacco use, prematurity, and birth year, that association was no longer statistically significant, and the authors concluded outcomes did not differ by breastfeeding status. How precise was the measure of cannabis exposure in this cohort? It was limited. Exposure was based on a positive maternal cannabis test at delivery, which does not capture dose, frequency, route, potency, or continued use after birth. The design also does not directly measure cannabinoid exposure through breast milk. Does this study address long-term attention or school-age behavior? No. The article states the study does not answer questions about long-term executive function, attention, school-age behavior, or dose-response risk. Developmental delay was identified through billing codes for delayed milestones or speech disorders rather than standardized developmental testing, and such codes can miss subtler neurodevelopmental effects. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).